Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia:A case report
作者机构：Department of PsychiatryShanghai Mental Health CenterShanghai 200030China School of MedicineShanghai Jiaotong UniversityShanghai 200025China Department of EndocrinologyShanghai Jiaotong University School of MedicineShanghai 9th HospitalShanghai 200011China
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2022年第10卷第21期
页 面：7495-7501页
核心收录：
学科分类：1002[医学-临床医学] 100205[医学-精神病与精神卫生学] 10[医学]
基 金：Supported by the National Natural Science Foundation of China,No.81873652 the Programs Foundation of Shanghai Mental Health Center,China,No.2020-QH-03
主 题：Hyperglycemia Liraglutide GLP-1 receptor agonist Schizophrenia Antipsychotics Case report
摘 要：BACKGROUND Antipsychotics are associated with abnormalities in glucose metabolism in patients with schizophrenia. Liraglutide, a GLP-1 receptor agonist, is Food and Drug Administration approved for the treatment of type 2 diabetes mellitus. However, ways to maintain the long-term stability of psychotic symptoms and balance the disadvantages of obesity, diabetes, and other metabolic disorders caused by antipsychotic medications remain unclear. In this study, we present a case of weight gain and hyperglycemia in a schizophrenia patient who received antipsychotic polypharmacy for 6 *** SUMMARY A 27-year-old man with olanzapine and sodium valproate-treated disorganized schizophrenia was admitted to a diabetes outpatient clinic. He was diagnosed with type 2 diabetes(fasting blood glucose, 20 mmol/L) and obesity(body mass index, 38.58 kg/m). The patient had been treated with glargine(40 IU/d) and metformin(1.5 g/d) and showed a poor response for 2 mo. Two years of liraglutide treatment resulted in stable blood glucose levels and weight loss in addition to a maintained stable mental status for a long time. The biological activities of GLP-1 significantly improved glucose levels and body weight in the schizophrenia patient treated with antipsychotic *** Liraglutide administration can be considered an effective alternative treatment for abnormalities in glucose metabolism in schizophrenia patients receiving antipsychotics.
维普期刊数据库